Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib

A randomized trial

Kim Brixen, Roland Chapurlat, Angela M. Cheung, Tony M. Keaveny, Thomas Fuerst, Klaus Engelke, Robert R. Recker, Bernard Dardzinski, Nadia Verbruggen, Shabana Ather, Elizabeth Rosenberg, Anne E. De Papp

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD)in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P

Original languageEnglish
Pages (from-to)571-580
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Bone Remodeling
Bone Density
Bone
Minerals
Spine
Institutional Practice
Placebos
Cathepsin K
Pelvic Bones
Finite Element Analysis
Private Practice
odanacatib
Haplorhini
Hip
Tomography
X-Rays
Outcome Assessment (Health Care)
Bone and Bones
Finite element method
X rays

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib : A randomized trial. / Brixen, Kim; Chapurlat, Roland; Cheung, Angela M.; Keaveny, Tony M.; Fuerst, Thomas; Engelke, Klaus; Recker, Robert R.; Dardzinski, Bernard; Verbruggen, Nadia; Ather, Shabana; Rosenberg, Elizabeth; De Papp, Anne E.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 2, 02.2013, p. 571-580.

Research output: Contribution to journalArticle

Brixen, K, Chapurlat, R, Cheung, AM, Keaveny, TM, Fuerst, T, Engelke, K, Recker, RR, Dardzinski, B, Verbruggen, N, Ather, S, Rosenberg, E & De Papp, AE 2013, 'Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 2, pp. 571-580. https://doi.org/10.1210/jc.2012-2972
Brixen, Kim ; Chapurlat, Roland ; Cheung, Angela M. ; Keaveny, Tony M. ; Fuerst, Thomas ; Engelke, Klaus ; Recker, Robert R. ; Dardzinski, Bernard ; Verbruggen, Nadia ; Ather, Shabana ; Rosenberg, Elizabeth ; De Papp, Anne E. / Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib : A randomized trial. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 2. pp. 571-580.
@article{451bff72fc8a455fb9b0b1816a623c0c,
title = "Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial",
abstract = "Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD)in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5{\%} greater with odanacatib than placebo (P",
author = "Kim Brixen and Roland Chapurlat and Cheung, {Angela M.} and Keaveny, {Tony M.} and Thomas Fuerst and Klaus Engelke and Recker, {Robert R.} and Bernard Dardzinski and Nadia Verbruggen and Shabana Ather and Elizabeth Rosenberg and {De Papp}, {Anne E.}",
year = "2013",
month = "2",
doi = "10.1210/jc.2012-2972",
language = "English",
volume = "98",
pages = "571--580",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib

T2 - A randomized trial

AU - Brixen, Kim

AU - Chapurlat, Roland

AU - Cheung, Angela M.

AU - Keaveny, Tony M.

AU - Fuerst, Thomas

AU - Engelke, Klaus

AU - Recker, Robert R.

AU - Dardzinski, Bernard

AU - Verbruggen, Nadia

AU - Ather, Shabana

AU - Rosenberg, Elizabeth

AU - De Papp, Anne E.

PY - 2013/2

Y1 - 2013/2

N2 - Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD)in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P

AB - Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD)in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P

UR - http://www.scopus.com/inward/record.url?scp=84873684246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873684246&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-2972

DO - 10.1210/jc.2012-2972

M3 - Article

VL - 98

SP - 571

EP - 580

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -